Updated from 4:19 p.m. ESTGenentech ( DNA) rose late Monday after its fourth-quarter results breezed past Wall Street's estimates. The South San Francisco, Calif., biotech made $594 million, or 55 cents a share, for the quarter ended Dec. 31. That's up from the year-ago $339 million, or 31 cents a share. Excluding certain items, earnings rose to 61 cents a share from 34 cents a year ago. Revenue rose to $2.71 billion from $1.89 billion a year earlier. Analysts surveyed by Thomson Financial were looking for a 56-cent profit on sales of $2.55 billion. U.S. product sales rose 38% from a year ago to $2.05 billion, led by a 36% gain in sales of cancer drug Avastin. Breast cancer drug Herceptin brought in $322 million in sales, up 29% from a year ago. Rituxan, a rheumatoid arthritis drug co-marketed with Biogen Idec ( BIIB), brought in $560 million, up 16%. Eye drug Lucentis posted sales of $217 million, compared with $153 million in the third quarter, and beyond Wall Street's expectations. The drug was approved in June 2006 to treat vision loss from age-related macular degeneration. The company's better-than-expected revenue was also partly due to unexpected sales of Avastin and Herceptin to Genentech's marketing partner Roche for distribution outside of the U.S. Those sales led to a 130% jump in sales to collaborators, to $191 million, the company said in its conference call after the close of trading.